AgomAb Therapeutics NV (NASDAQ:AGMB) Stock Has Consensus Price Target of $37.50

AgomAb Therapeutics NV (NASDAQ:AGMB) has been given a consensus rating of “Moderate Buy” by the nine research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $37.50.

AGMB has been the topic of a number of research reports. Johnson Rice reiterated a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday. Cantor Fitzgerald began coverage on AgomAb Therapeutics in a research note on Wednesday, August 19th. They set an “overweight” rating for the company. Wall Street Zen lowered shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 27th. HC Wainwright restated a “buy” rating on shares of AgomAb Therapeutics in a report on Wednesday. Finally, Piper Sandler began coverage on AgomAb Therapeutics in a report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 target price on the stock.

Key Stories Impacting AgomAb Therapeutics

Here are the key news stories impacting AgomAb Therapeutics this week:

• Positive Sentiment: Director David Epstein purchased 10,000 AGMB shares at an average price of $8.88, investing approximately $88,800 and increasing his direct ownership by 66.7% to 25,000 shares. Insider buying can signal management confidence that the stock is undervalued. AgomAb Therapeutics Director Buys 10,000 Shares
• Positive Sentiment: HC Wainwright raised its EPS forecasts for every year from fiscal 2026 through fiscal 2030. The revisions were modest but consistently favorable, with estimated losses narrowing to $1.91 per share in 2026, $2.02 in 2027, $1.75 in 2028, $1.81 in 2029 and $1.79 in 2030. The firm maintained its “Buy” rating.
• Neutral Sentiment: Analyst sentiment remains broadly constructive, with the company described as having a “Moderate Buy” consensus and several firms maintaining Buy or Overweight ratings. However, one research firm recently downgraded the shares to Sell, highlighting disagreement about the company’s outlook.
• Negative Sentiment: AgomAb is still expected to report losses, including a consensus estimate of approximately $1.83 in negative EPS for the current year. As a clinical-stage biotechnology company, its valuation remains dependent on progress in programs such as AGMB-129, while the shares continue to trade below their key moving averages.

AgomAb Therapeutics Stock Performance

Shares of AgomAb Therapeutics stock opened at $9.05 on Friday. The firm’s 50 day simple moving average is $11.52 and its two-hundred day simple moving average is $11.75. AgomAb Therapeutics has a 12-month low of $7.92 and a 12-month high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. Sell-side analysts anticipate that AgomAb Therapeutics will post -1.77 earnings per share for the current year.

Insider Buying and Selling at AgomAb Therapeutics

In other AgomAb Therapeutics news, CEO Tim Jasper Knotnerus purchased 6,000 shares of the stock in a transaction dated Monday, October 5th. The stock was acquired at an average cost of $8.48 per share, for a total transaction of $50,880.00. Following the acquisition, the chief executive officer owned 16,823 shares in the company, valued at $142,659.04. This trade represents a 55.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David R. Epstein bought 10,000 shares of the stock in a transaction on Wednesday, October 21st. The shares were bought at an average cost of $8.88 per share, with a total value of $88,800.00. Following the purchase, the director owned 25,000 shares of the company’s stock, valued at $222,000. This trade represents a 66.67% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 41,000 shares of company stock worth $357,080 in the last ninety days.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company’s research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.

Agomab’s lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn’s disease, a condition in which scar tissue can narrow the intestine and contribute to complications.

The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.